Biotech RadarJobs updated

COMPANY

Integro Theranostics

integrotheranostics.com ↗

Clinical Phase 2

Keywords: oncology Breast Cancer Invasive Duct Carcinoma of Breast Lung Cancers Non Small Cell Lung Cancer LS301-IT

Profile checked Oct 10, 2026

3Trials (company is sponsor)

Timeline

  1. Trial start Phase 2: Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer source ↗
  2. Trial start Phase 1: A Single Dose, Open-Label, Dose-escalation Study of the Safety and Imaging Characteristics of LS301-IT for Intraoperative Imaging of Lung Cancer source ↗
  3. Trial start Phase 1/Phase 2: LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer source ↗

Clinical trials (lead sponsor) 3

RecordTitlePhaseStatusStartPrimary completion
NCT05900986LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast CancerPhase 1/Phase 2CompletedJul 14, 2023Oct 6, 2025 (actual)
NCT06713564A Single Dose, Open-Label, Dose-escalation Study of the Safety and Imaging Characteristics of LS301-IT for Intraoperative Imaging of Lung CancerPhase 1CompletedNov 7, 2024May 6, 2026 (actual)
NCT07276789Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung CancerPhase 2RecruitingDec 8, 20252026-08 (estimated)
Feedback